RxDoctor Payments Data

S Janel Beatie, MD

Internal Medicine · Tomball, TXNPI 1801982020

Payments from drug & device makers

$5,071in general payments, 2019–2025

Across 297 payments — averaging $17.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$918
  • Radius Health, Inc.$567
  • Novo Nordisk$479
  • AstraZeneca$365
  • Pfizer$248
  • Novartis$240
  • plus $2K from 38 others

What the payments were for

  • Food & beverage$5,00199%
  • Education$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,071 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$698,461
Medicare patients
550
Services billed
27,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide174$227,713
JardianceEmpagliflozin124$157,353
OzempicSemaglutide106$147,505
FarxigaDapagliflozin Propanediol106$118,617
EliquisApixaban117$108,628
RybelsusSemaglutide49$97,488
TymlosAbaloparatide21$70,628
TrulicityDulaglutide43$60,378
XareltoRivaroxaban46$54,549
ProliaDenosumab30$53,475
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$48,706
Tresiba Flextouch U-200Insulin Degludec19$47,854
RexultiBrexpiprazole28$41,657
SynthroidLevothyroxine Sodium401$37,121
GemtesaVibegron37$34,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$117$288,091217 claims
Novo NordiskOzempic, Rybelsus$479$244,993155 claims
Boehringer IngelheimJardiance$18$157,353124 claims
PfizerEliquis, Nurtec Odt$248$128,116128 claims
AstraZenecaFarxiga$365$118,617106 claims
AmgenProlia, Evenity (2 Syringes)$918$80,72441 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$136$74,892111 claims
Radius Health, Inc.Tymlos$567$70,62821 claims
Johnson & JohnsonXarelto$202$54,54946 claims
AbbVieSynthroid, Namzaric$181$47,533418 claims
Otsuka America Pharmaceutical, Inc.Rexulti$16$41,65728 claims
Sumitomo Pharma America, Inc.Gemtesa$25$34,22737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →